drugs be COVID-XX, thank nature direct-acting of needed severe you, From evolving begin breakthrough challenging clear us on been viral will Thank the has the you Slide diseases. is this with of beginning everyone Good against to viral Jonae. very today. that afternoon, discode antiviral disease. and to X. joining Today for I will it Atea's address combination goal
the in learned we what year. So past
three surges, six variant disease Delta what viral have such months summer seeing with to which with with variant dealing evolving are Omicron. pandemic now We from and is last we with as major the to within rapidly
now the constantly This to society see which and on is long which of COVID long-term to economic with vaccine starting have urgently the virus. virus, monoclonal and as is will health significant well. therapeutics And that continue public to evading impact mutating it's also effect are mechanism and deal We individuals challenging of different actions antibodies. and rapidly all we clear of several most need with
inhibitor this have successful regimens protease resistant drugs the nucleotide potential RNA AT-XXX many low efficacy. of if both mitigate We can While will of with enhance bag in of nuke has see rapid of good regimen combination COVID-XX. combination we has this believe to with Historically that issue barrier weeks the even and learned and against the Nucleotide protease class that resistance efficacy been also recently choice strains, we replication class to COVID-XX. where drugs a preferred be against immunosuppressed all inhibitors the a has resistance severe the shown have the diseases viral our to continue for for the development months. individuals to for treatment viral or Bemnifosbuvir especially
the protease Our a team can the has the of with Bemnifosbuvir we long-term COVID-XX. inhibitor leading over in of viruses we for therapies solution the RNA and for efforts that believe several in and deliver combination experience years combination again treatment developing
treatment HCV in regimen. result may C with duration, eliminate licensing with in hepatitis the to a and HCV, improved advanced the in HCV pangenotypic of to convenience which recent combined timeline treatment program is showed of Turning patients better will the combination disease. our and Bemnifosbuvir for need still liver best-in-class accelerate Ruzasvir There the
global in billion is will discuss The HCV market. As and the C hepatitis XX% of US, $X the approached call. launched with John the XXXX the market representing in later market about
lack platform. analogue disease generated mosquito-borne program Dengue large and with disease third our the from clinical antiviral our is viral global We treatments. a most further are also fever nucleotide purine advancing AT-XXX, prevalent of
X Phase as in study late the to dengue as in study well AT-XXX endemic countries conducted a trial a We clinical year US. have conducting now the in last Phase completed progress challenge X will successfully
Let's now review our strategy for COVID-XX.
we mutations nuke Moving the for a with X. been is viral of also to of protease as peer-reviewed as concern combination and variants choice highly that RNA a to journal as the chain mechanism you this high dual the also potential Uniquely which, function to Communication. conserved believe is Thus end replication. especially recently enzyme, is antiviral to I of of the both viral a to It or the MoA create the Bemnifosbuvir MoA has the as viral function these terminator with activity know Bemnifosbuvir inhibiting genome has inhibitor and Nature is is introducing MoA the treatment replication I've protein polymerase this also the in published resistance which may of a critical inhibition new Slide and in RNA to a Bemnifosbuvir provide said targets. a shown action were is for provide as It critical molnupiravir. routes. be in a will with to new which targets the for transcription well spike function, vision COVID-XX. across without polymerase any barrier viral of relating details the
we during well hand over the and profile for to uniquely treatment will also maintain only call reproductive Janet. believe and but was it MoA, which to-date, is and this well no safe to Bemnifosbuvir is unique presentation. all In safety it Bemnifosbuvir makes anticipate as regimen with review can Of now continue HCV not So shown in toxicity based is that evolve. this will COVID-XX generally activity non-teratogenic that combination be virus suited, I will mitogenic on not the its for this to tolerated. studies which clinical we Bemnifosbuvir note,
